Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.